Center Laboratories, Inc. (4123) AI Stock Analysis

Center Laboratories, Inc.

(TPEx:4123)

Select Model

Rating:55Neutral

Price Target:TWD 29.00▲(2.11% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by weak and inconsistent cash generation and a bearish technical trend. A strengthened balance sheet and attractive dividend yield provide support, but they do not fully offset the earnings-quality and momentum risks.

Positive Factors

Balance Sheet ResilienceA large equity base and moderate leverage provide financial resilience and reduce balance-sheet strain during operating volatility. This gives Center Laboratories greater capacity to absorb weaker periods, maintain strategic flexibility, and support operations over the next several quarters.

Negative Factors

Weak Cash ConversionOperating cash flow that remains far below reported net income raises concerns about the quality and repeatability of earnings. Weak conversion can limit internally funded investment, increase reliance on external financing, and make the recent profit rebound less durable.

Center Laboratories, Inc. (4123) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 22.38B
Dividend Yield: 6.15%
Average Volume (3M): 1.62M
Price to Earnings (P/E): 23.8
Beta (1Y): 0.12
Revenue Growth: 3.63%
EPS Growth: ―
Country: TW
Employees: 182
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Center Laboratories, Inc. Business Overview & Revenue Model

Company Description

Center Laboratories, Inc. operates as a Taiwanese pharmaceutical enterprise, with its primary focus lying in the manufacturing and distribution of various medical products across Taiwan. Beyond its core drug operations, the firm is heavily invested i...

Center Laboratories, Inc. Financial Statement Overview

Summary

The balance sheet is strong and improving, but volatile profitability, negative 2025 EBIT, weak operating cash flow, and negative free cash flow materially limit financial quality.

Income Statement

52Neutral

Balance Sheet

78Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	1.66B	1.52B	1.62B	1.39B	767.72M	500.11M
Gross Profit	680.07M	621.26M	748.95M	618.09M	406.27M	259.66M
EBITDA	12.09B	11.95B	-232.41M	-765.79M	232.50M	2.73B
Net Income	1.02B	9.32B	-1.10B	-995.42M	-575.62M	1.82B
Balance Sheet
Total Assets	23.97B	34.63B	25.54B	27.00B	25.19B	30.44B
Cash, Cash Equivalents and Short-Term Investments	3.85B	974.21M	3.23B	4.55B	2.56B	5.09B
Total Debt	4.10B	4.70B	6.53B	5.62B	3.47B	5.27B
Total Liabilities	6.81B	8.14B	7.48B	6.79B	5.94B	9.35B
Stockholders Equity	17.16B	26.49B	18.05B	19.76B	19.25B	18.94B
Cash Flow
Free Cash Flow	249.78M	-181.05M	234.89M	-1.14B	-197.43M	-364.79M
Operating Cash Flow	405.33M	27.16M	415.71M	-963.44M	-189.88M	-358.14M
Investing Cash Flow	4.16B	1.65B	-757.51M	-129.01M	5.18B	-655.88M
Financing Cash Flow	-1.55B	-2.88B	79.09M	2.00B	-4.46B	358.10M

Center Laboratories, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4123 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4105	79Outperform	TWD 20.44B	12.48	―	5.48%	4.54%	-7.38%
TW:6620	70Outperform	TWD 20.83B	66.76	―	1.52%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4123	55Neutral	TWD 22.38B	23.82	―	6.15%	3.63%	―
TW:4743	42Neutral	TWD 22.59B	-102.60	―	―	14.79%	84.54%

* General Sector Average

Performance Comparison

TW:4123 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4123	Center Laboratories, Inc.	28.40	-5.63	-16.55%
TW:4105	TTY Biopharm Company Limited	82.10	7.64	10.26%
TW:4743	Oneness Biotech Co., Ltd.	46.25	-16.25	-26.00%
TW:6620	Handa Pharmaceuticals Inc	136.50	17.95	15.14%
TW:7686	A-Top Health Biotech Co., Ltd.	729.00	209.00	40.19%
TW:7827	HanchorBio Inc.	119.00	49.00	70.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Center Laboratories, Inc. AI Stock Analysis